Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.3152W HIGH $28.14
Volume
115.08 K
Value Traded
6.86 M
Short % Float
5.02%
+0.96%Week
-7.98%1 Month
-40.9%3 Month
-53.32%6 Month
+9.69%5 Year
+5,706.24%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
221.18 M
EPS (TTM)
1.03
P/E Ratio
12.22
Ent. Value
138.67 M
Total Shares
17.59 M
Float Shares
16.51 M
Insiders
6.16%
Institutions
91.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NATR Catalyst Timeline
Dated clinical, regulatory and corporate events for Nature's Sunshine Products, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nature's Sunshine Products, Inc.
64Total events
0Upcoming
8Tier-1 (high impact)
2011 to 2017Coverage
Event history 50
◆Management ChangeCorporate
Joseph W. Baty appointed Executive Vice President and Chief Financial Officer
◆Other Regulator MilestoneEx-US Regulatory
Expected to obtain direct-selling license in China in 2016
▲Other Regulator MilestoneEx-US Regulatory
China market entry progressing on schedule for launch in late 2015
◆Product LaunchPost-Market
E-commerce channel rollout in China expected in second-half of 2015
▼Equity OfferingCorporate
Repurchased $3.8 million of common stock in first half of fiscal 2015
▼Restructuring LayoffsCorporate
Announced plan to streamline operations, cease Vietnam operations, eliminate 100-130 positions
▲Manufacturing MilestoneCMC / Inspection
New R&D center and medical clinic opening this month (February 2015)
▲Partnership / LicenseCorporate
Closed $46.2 million private placement and joint venture with Fosun Pharma for China market entry
▼Equity OfferingCorporate
Closed private placement of 2.854 million shares at $16.19 per share to Fosun Pharma
◆Other Regulator MilestoneEx-US Regulatory
Anticipated closing of joint venture and private placement in Q3 2014
◆Timing GuidancePresentation
Anticipated closing of Fosun Pharma JV and private placement in Q3 2014
▲Partnership / LicenseCorporate
Strategic alliance with Fosun Pharma to form China joint venture
▼Equity OfferingCorporate
Fosun Pharma to acquire ~15% stake via private placement for ~$46.3M
▲Partnership / LicenseCorporate
Resolved contract dispute with General Dealer in Russia; new three-year agreement effective April 1, 2014
▲Product LaunchEquolibriumPost-Market
Launch of Equolibrium prostate balancing product
prostate balancingsource ↗
▲Product LaunchIN.FORMPost-Market
Launched IN.FORM weight management program in U.S. in March 2014
weight managementsource ↗
▲Partnership / LicenseCorporate
China joint venture with Fosun Pharma; private placement of 2.9M shares for $44.8M
▲Product LaunchSLMsmartPost-Market
Launched SLMsmart weight management line in South Korea
weight managementsource ↗
●Management ChangeCorporate
Hired Jeffrey Ten as Vice President of New Markets and Channel Development
▲Manufacturing MilestoneCMC / Inspection
Will break ground on new $2 million R&D center in next few months
▲Product LaunchAnxiousLessPost-Market
Launch of AnxiousLess situational anxiety product
situational anxietysource ↗
▲Product LaunchPost-Market
Launched new point-of-purchase merchandizing tools in October 2013
Past FDA Catalysts and PDUFA Decisions
How NATR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Nature's Sunshine Products, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NATR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.10% Owner | Buy | 20,000 1,944,486 held | $14.69 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NATR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NATR for Q2 2026. | ||||
NATR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NATR ranks across every disease it competes in
Competitive Position is a premium feature
See how NATR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNATR News
NATREARNINGS RELEASE Exhibit FOR IMMEDIATE RELEASE NATURE'S SUNSHINE PRODUCTS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS Second quarter net sales of $81.3 million were down 9.0% year-over-year Net loss of $0.2 million att
NATURE'S SUNSHINE PRODUCTS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS LEHI, Utah, August 8, 2017 - Nature's Sunshine Products, Inc. (NASDAQ: NATR), a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal care pro
Read more →NATRFourth Quarter 2016 Financial Highlights
NATURE'S SUNSHINE PRODUCTS REPORTS FOURTH QUARTER 2016 FINANCIAL RESULTS LEHI, Utah, March 7, 2017 - Nature's Sunshine Products, Inc. (NASDAQ: NATR), a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal care prod
Read more →NATRJBATY PRESS RELEASE Exhibit FOR IMMEDIATE RELEASE Nature's Sunshine Products announces new chief financial officer
Nature's Sunshine Products announces new chief financial officer LEHI, Utah, October 31, 2016 - Nature's Sunshine Products (NASDAQ: NATR) ("NSP"), a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal care product
Read more →NATREARNINGS RELEASE Exhibit FOR IMMEDIATE RELEASE NATURE'S SUNSHINE PRODUCTS REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS Net sales revenue of $89.4 million was up 10.0% year-over-year; up 11.5% year-over-year on a local c
NATURE'S SUNSHINE PRODUCTS REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS LEHI, Utah, August 8, 2016 - Nature's Sunshine Products, Inc. (NASDAQ: NATR), a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal care pro
Read more →NATRcyber security threats and exposure to data loss; its reliance on its information technology infrastructure; the sufficiency of trademarks and other intellectual property rights; changes in tax laws, treaties or regulati
NATURE'S SUNSHINE PRODUCTS ANNOUNCES THE RETIREMENT OF STEVE BUNKER AS EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER AND TREASURER LEHI, Utah, March 7, 2016 - Nature's Sunshine Products, Inc. (NASDAQ: NATR), a leading natural health and wellness company engaged in the manufa
Read more →NATRFourth Quarter 2015 Financial Highlights
NATURE'S SUNSHINE PRODUCTS REPORTS FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS LEHI, Utah, February 25, 2016 - Nature's Sunshine Products, Inc. (NASDAQ: NATR), a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and
Read more →NATRNATURE S SUNSHINE PRODUCTS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS Net sales revenue of $79.6 million was down 14.8% year-over-year; down 8.8% year-over-year on a local currency basis Earnings
NATURE S SUNSHINE PRODUCTS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS Net sales revenue of $79.6 million was down 14.8% year-over-year; down 8.8% year-over-year on a local currency basis Earnings from continuing operations of $0.08 per diluted share Repurchased $6.1 million
Read more →NATRNATURE S SUNSHINE PRODUCTS REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS Net sales revenue of $81.2 million was down 12.5% year-over-year; down 7.7% year-over-year on a local currency basis Diluted
NATURE S SUNSHINE PRODUCTS REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS Net sales revenue of $81.2 million was down 12.5% year-over-year; down 7.7% year-over-year on a local currency basis Diluted EPS of $0.12, or $0.19, when excluding charges associated with the restructuring
Read more →NATRNATURE S SUNSHINE PRODUCTS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS Third consecutive quarter of net sales growth for NSP Americas and Synergy Europe China market entry progressing on schedule f
NATURE S SUNSHINE PRODUCTS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS Third consecutive quarter of net sales growth for NSP Americas and Synergy Europe China market entry progressing on schedule for launch in late 2015 Announced plan to streamline operations and refocus Comp
Read more →NATRNATURE S SUNSHINE PRODUCTS REPORTS FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS NSP Russia, Central and Eastern Europe sales continue to be depressed Second consecutive quarter of net sales g
NATURE S SUNSHINE PRODUCTS REPORTS FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS NSP Russia, Central and Eastern Europe sales continue to be depressed Second consecutive quarter of net sales growth for NSP United States, NSP Canada and Synergy Europe China market entry i
Read more →NATRNATURE S
NATURE S SUNSHINE PRODUCTS ANNOUNCES LEHI, UTAH, February 6, 2015 Nature s Sunshine Products, Inc. (NASDAQ:NATR), a leading natural health and wellness company engaged in the manufacture and direct sale of premium-quality nutritional and personal care products, today announced t
Read more →NATRNATURE S SUNSHINE PRODUCTS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS Fifth consecutive quarter of record sales at Synergy WorldWide, driven by South Korea, Japan and a return to growth in Europe
NATURE S SUNSHINE PRODUCTS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS Fifth consecutive quarter of record sales at Synergy WorldWide, driven by South Korea, Japan and a return to growth in Europe NSP United States and NSP Canada show net sales growth for the first time since
Read more →NATRNATURE S SUNSHINE ANNOUNCES CLOSING OF PRIVATE PLACEMENT AND JOINT VENTURE AGREEMENT WITH FOSUN PHARMA Closed $46.2 million private placement transaction to fund China market entry Fosun Pharma acqu
NATURE S SUNSHINE ANNOUNCES CLOSING OF PRIVATE PLACEMENT AND JOINT VENTURE AGREEMENT WITH FOSUN PHARMA Closed $46.2 million private placement transaction to fund China market entry Fosun Pharma acquired 15% stake in Nature s Sunshine Declared $1.50 per share special cash divid
Read more →NATRNATURE S SUNSHINE PRODUCTS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS Fourth consecutive quarter of record sales at Synergy WorldWide, driven by South Korea and Japan Strategic alliance with Fosu
NATURE S SUNSHINE PRODUCTS REPORTS SECOND QUARTER 2014 Fourth consecutive quarter of record sales at Synergy WorldWide, driven by South Korea and Japan Strategic alliance with Fosun Pharma to enter China through both direct selling and retail distribution channels Continuing w
Read more →NATRNATURE S SUNSHINE ANNOUNCES STRATEGIC ALLIANCE WITH FOSUN PHARMA Nature s Sunshine enters China, the fastest growing direct selling market in the world, with local strategic partner Companies will f
NATURE S SUNSHINE ANNOUNCES STRATEGIC ALLIANCE WITH FOSUN PHARMA Nature s Sunshine enters China, the fastest growing direct selling market in the world, with local strategic partner Companies will form a joint venture to market and distribute Nature s Sunshine and Synergy prod
Read more →NATRNATURE S SUNSHINE PRODUCTS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS Third consecutive quarter of record-setting sales at Synergy Worldwide, driven by South Korea and Japan. Overall sales were fl
NATURE S SUNSHINE PRODUCTS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS Third consecutive quarter of record-setting sales at Synergy Worldwide, driven by South Korea and Japan. Overall sales were flat year-over-year, reflecting weakness in Ukraine. Operating income increased 3.
Read more →NATRNATURE S SUNSHINE PRODUCTS REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS Fourth quarter net sales revenue growth of 5.7 percent year-over-year (6.8 percent in local currency) Significa
NATURE S SUNSHINE PRODUCTS REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS Fourth quarter net sales revenue growth of 5.7 percent year-over-year (6.8 percent in local currency) Significant investment spending, resulting in lower operating income Board of Directors
Read more →About Nature's Sunshine Products, Inc.
Headquarters2901 WEST BLUEGRASS BLVD., LEHI, UT, 84048
BIOPHARMAWATCH ELITE PLUS
Trade the next NATR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime